Novozymes launches animal-free cell culture ingredients product range

Published: 31-May-2007
Ingredients Pharmaceutical

UK-based biotech company Novozymes has launched a range of animal-free recombinant ingredients developed specifically for industrial scale mammalian cell culture.


UK-based biotech company Novozymes has launched a range of animal-free recombinant ingredients developed specifically for industrial scale mammalian cell culture.

This is the first product launch from the company's new biopharmaceutical ingredients business, which is dedicated to developing animal-free recombinant ingredients to support biopharmaceutical production.

'Our biopharmaceutical customers can now achieve the performance of protein-rich media on an industrial scale without the need to compromise on consistency or safety,' said Peter Rosholm, vice president for the biopharmaceutical ingredients business.

See more

You may also like

Ingredients

Novozymes reports a good year in 2014

Read more
Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%

Trending Articles

  1. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
  2. Roquette opens pharmaceutical innovation centre in Brazil The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
  3. Takeda and Innovent Biologics partner to advance next-gen oncology medicines Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
  4. COREX Logistics strengthens leadership team with new COO appointment 18+ year supply chain expert joins Irish pharmaceutical logistics company to spearhead operational expansion across 80+ country network
  5. Pharma Tech Industries names Sam Ricchezza as Senior Managing Advisor, Commercial Operations Mr. Ricchezza is the latest addition to an executive team tasked with continuing the CMO’s recent growth trends

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Diversity aids a biotech boom

The biotech sector is boosted by invention and shows no sign of slowing. Biopharmaceutical pipelines are broadening and production techniques improving. Susan Birks reports
Research & Development

Novozymes Biopharma enters agreement with leading vaccine company

To conduct research on a novel subunit vaccine complex based on albumin fusion technology
Research & Development

Novozymes Biopharma to offer drug-albumin conjugation platform with ThioLogics

New partnership to offer serum-stable drug-albumin conjugation capability
Manufacturing

GSK uses Novozymes\' Veltis half-life extension technology in once-weekly diabetes drug

Novozymes technology used in recently approved Eperzan type 2 diabetes treatment
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Finance

Novozymes reports 4% increase in sales in Q1

Biopharma sales rise by 22%
Subscribe now